Blog

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009,...

Read more +

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...

Read more +

HUTCHINSON, Kan. – May 12, 2022 – Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA, announced today the...

Read more +

SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 /EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract...

Read more +

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on...

Read more +

View More